Deltex Medical Group (DEMG)

Sector:

Health Care

Index:

FTSE AIM All-Share

   Trade now with Barclays Stockbrokers   Trade now with Barclays   Sponsored by Barclays Stockbrokers

 1.23p
   
  • Change Today:
      0.000p
  • 52 Week High: 2.38p
  • 52 Week Low: 0.76p
  • Currency: UK Pounds
  • Shares Issued: 492.66m
  • Volume: 212,000
  • Market Cap: £6.04m
  • RiskGrade: 447
  • Beta: 0.60

Deltex Medical Group sees losses narrow despite faltering revenue growth

By Duncan Ferris

Date: Wednesday 09 May 2018

LONDON (ShareCast) - (Sharecast News) - Oesophageal Doppler monitoring firm Deltex Medical Group saw its shares dip on Wednesday after the company revealed that, although its 2017 pre-tax loss had narrowed, the company's revenues declined 6% to £5.9m.
The company attributed the revenue decline to a £500,000 decline from UK probe sales, while international sales also fell, by 5% to £1.9m, but offset by 5% growth in US revenues to £2m.

Despite this, the company managed to pare its pre-tax loss by 16%.

Management said it achieved savings by bringing probe production in house and putting new manufacturing processes in place, resulting in a £400,000 reduction in its operating losses.

Nigel Keen, chairman of Deltex Medical, said: "The progress made towards operating cash breakeven and profitability through improved consumable margins and reduced overheads made during 2017 was partially offset by a disappointing second half sales performance."

In the meantime, Deltex Medical also announced the launch of the TrueVue Loops display software on its CardioQ-ODM+ haemodynamic monitoring platform.

The AIM-traded company said the software will allow users to view a simultaneous display of a patient's aortic blood flow velocity, taken directly from the TrueVue Doppler probe, and aortic blood pressure, from a continuous blood pressure device.

Ewan Phillips, chief executive of Deltex Medical, said: "By giving doctors, for the first time ever, a complete and continuous picture of a patient's central haemodynamic status the Loops should take the science of haemodynamics forward in both intensive and peri-operative care. The initial focus on vaso-active drugs offers the possibility of Deltex building a strong competitive advantage in this area to match its existing strength in fluid management."

Doctors from Paris' Lariboisiere Hospital developed the software with a focus on using TrueVueTM Loops to identify the effects of administering vaso-active drugs and to guide their safe administration.

As of 1247 BST, Deltex Medical Group's shares were down 7.14% at 1.30p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

DEMG Market Data

Currency UK Pounds
Share Price 1.23p
Change Today 0.000p
% Change 0.00 %
52 Week High 2.38p
52 Week Low 0.76p
Volume 212,000
Shares Issued 492.66m
Market Cap £6.04m
Beta 0.60
RiskGrade 447

DEMG Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
47.68% below the market average47.68% below the market average47.68% below the market average47.68% below the market average47.68% below the market average
17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average
Price Trend
66.5% below the market average66.5% below the market average66.5% below the market average66.5% below the market average66.5% below the market average
62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average62.16% below the sector average
Income Not Available
Growth
50.91% below the market average50.91% below the market average50.91% below the market average50.91% below the market average50.91% below the market average
58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

DEMG Dividends

No dividends found

Trades for 15-Nov-2018

Time Volume / Share Price
15:58 200,000 @ 1.20p
12:16 12,000 @ 1.25p

DEMG Key Personnel

Chair Nigel J Keen
Finance Director Jonathan David Shaw
CEO Andy Mears

Top of Page